Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (AKRO)
NASDAQ:AKRO
Akero Therapeutics (AKRO) Stock Price & Analysis
441 Followers
AKRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.25 - $53.77
Previous Close$28.12
Volume412.32K
Average Volume (3M)814.67K
Market Cap
$1.94B
Enterprise Value$1.08B
Total Cash (Recent Filing)$903.66M
Total Debt (Recent Filing)$35.55M
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
Aug 13, 2024EPS Estimate
-$0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.20
Shares Outstanding69,151,007
10 Day Avg. Volume1,029,626
30 Day Avg. Volume814,675
Standard Deviation0.31
R-Squared0.00281
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)3.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.96
Forecast
1Y Price Target
$48.43Price Target Upside72.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Akero Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Outcomes study will help to reduce the time course for a potential full approval of EFX, as well as to facilitate a possible expansion of the drug's application.
Drug DevelopmentEfruxifermin continues to be one of the most exciting MASH drug candidates in development from conversations and polling of physicians.
Financial PerformanceAnalyst recommends a BUY rating with a price target of $56.
Bears Say
Competitive DynamicsThe presence of competitive dynamics and limited near-term commercial certainty make the risk/reward of Akero shares balanced.
Safety IssuesEfruxifermin's safety issues, such as gastrointestinal side effects and bone density loss, may limit its use to more advanced patients.
Trial ResultsThe SYMMETRY trial reported 36-week data, and the study did not demonstrate a statistically significant difference of EFX in improving liver fibrosis compared to placebo.
---
Ownership Overview
31.85% Insiders
29.78% Mutual Funds
13.34% Other Institutional Investors
25.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKRO FAQ
What was Akero Therapeutics Inc’s price range in the past 12 months?
Akero Therapeutics Inc lowest stock price was $11.25 and its highest was $53.77 in the past 12 months.
What is Akero Therapeutics Inc’s market cap?
Currently, no data Available
When is Akero Therapeutics Inc’s upcoming earnings report date?
Akero Therapeutics Inc’s upcoming earnings report date is Aug 13, 2024 which is in 17 days.
How were Akero Therapeutics Inc’s earnings last quarter?
Akero Therapeutics Inc released its earnings results on May 10, 2024. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$0.902 by $0.002.
Is Akero Therapeutics Inc overvalued?
According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued.
Does Akero Therapeutics Inc pay dividends?
Akero Therapeutics Inc does not currently pay dividends.
What is Akero Therapeutics Inc’s EPS estimate?
Akero Therapeutics Inc’s EPS estimate is -$0.83.
How many shares outstanding does Akero Therapeutics Inc have?
Akero Therapeutics Inc has 69,151,010 shares outstanding.
What happened to Akero Therapeutics Inc’s price movement after its last earnings report?
Akero Therapeutics Inc reported an EPS of -$0.9 in its last earnings report, beating expectations of -$0.902. Following the earnings report the stock price went down -5.529%.
Which hedge fund is a major shareholder of Akero Therapeutics Inc?
Among the largest hedge funds holding Akero Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Akero Therapeutics Inc’s shares valued at 69M.
---
Akero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.43 (72.23% Upside)
$48.43 (72.23% Upside)
Blogger Sentiment
Bullish
AKRO Sentiment 71%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 905.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $417.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.56%
12-Months-Change
Fundamentals
Return on Equity
-31.11%
Trailing 12-Months
Asset Growth
161.52%
Trailing 12-Months
Company Description
Akero Therapeutics Inc
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
---
AKRO Stock 12 Month Forecast
Average Price Target
$48.43
▲(72.23% Upside)
Technical Analysis
Best Analysts Covering AKRO
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+12.45%
reiterated a buy rating 2 months ago
Copying Edward Nash's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.45% per trade.
---